About the Company
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AXSM News
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Axsome Therapeutics Inc (NASDAQ:AXSM) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy ...
What Analysts Are Saying About Axsome Therapeutics Stock
Analysts have recently evaluated Axsome Therapeutics and provided 12-month price targets. The average target is $123.46, ...
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
Axsome Therapeutics AXSM announced encouraging data from the phase III SYMPHONY study on its investigational narcolepsy drug AXS-12. The study achieved its primary endpoint of a rapid and significant ...
Axsome's sleep disorder drug succeeds in late-stage trial, shares rise
Axsome Therapeutics said on Monday its experimental therapy cut the frequency of disruptive episodes of muscle weakness tied to a sleep disorder called narcolepsy in a late-stage trial.
Optimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite Challenges
Leerink Partners analyst Marc Goodman has maintained their bullish stance on AXSM stock, giving a Buy rating yesterday. Marc Goodman has given ...
Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy
Axsome clinched a late-stage victory for its chronic sleep disorder candidate AXS-12, which demonstrated significant ...
Axsome Therapeutics files patent for microparticles containing bupropion for treating depression
Discover Axsome Therapeutics' innovative patent for bupropion microparticles, optimized for treating depression. Learn about specific particle size ranges and compositions for enhanced drug delivery.
Axsome Therapeutics announces toplines results from CRESCENDO survey of patients with narcolepsy type 1
Axsome Therapeutics announces toplines results from CRESCENDO survey of patients with narcolepsy type 1: New York Wednesday, March 27, 2024, 17:00 Hrs [IST] Axsome Therapeutics, I ...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved ...
Axsome Therapeutics' Phase 3 SYMPHONY Study In Narcolepsy Meets Primary Goal
(RTTNews) - Axsome Therapeutics, Inc. (AXSM) Monday said the Phase 3 SYMPHONY study of its drug candidate AXS-12 for the treatment of narcolepsy met its primary goal. Narcolepsy is a brain and nervous ...
Axsome Triumphs Over Major Depressive Disorder With Auvelity
Since Auvelity consists of two active ingredients, its mechanism of action is complex and is based on both the inhibition of ...
Loading the latest forecasts...